Abstract
Although cyst(e)ine is nutritionally a non-essential amino acid, lymphoid cells cannot synthesize it, rendering their growth dependent on uptake of cyst(e)ine from their micro-environment. Accordingly, we previously suggested that the xc − plasma membrane cystine transporter provided a target for lymphoid cancer therapy. Its inhibition could lead to cyst(e)ine deficiency in lymphoma cells via reduction of both their cystine uptake and cysteine supply by somatic cells. In this study, using rat Nb2 lymphoma cultures, drugs were screened for growth arrest based on xc − inhibition. Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the xc − transporter. It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of xc −-mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid. Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures. In rats (n = 13), sulfasalazine (i.p.) markedly inhibited growth of well-developed, rapidly growing rat Nb2 lymphoma transplants without apparent side-effects. Reduced, macrophage-mediated supply of cysteine was probably involved. In five rats, 90–100% tumor growth suppression, relative to controls, was obtained. The xc − cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Poplack DG, Kun LE, Magrath IT, Pizzo PA . Leukemias and lymphomas of childhood In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology 4th edn JB Lippincott: Philadelphia 1993 pp 1792–1818
Gout PW, Horsman DE, Fox K, de Jong G, Ma S, Bruchovsky N . The rat Nb2 lymphoma: a novel model for tumor progression Anticancer Res 1994 14: 2485–2492
Heppner GH, Miller FR . The cellular basis of tumor progression Int Rev Cytol 1998 177: 1–56
Iglehart JD, York RM, Modest AP, Lazarus H, Livingston DM . Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin J Biol Chem 1977 252: 7184–7191
Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR . Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells Leukemia 1997 11: 1329–1337
Gmünder H, Eck H-P, Dröge W . Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones Eur J Biochem 1991 201: 113–117
Broome JD, Jeng MW . Promotion of replication in lymphoid cells by specific thiols and disulfides in vitro J Exp Med 1973 138: 574–592
Ishii T, Hishinuma I, Bannai S, Sugita Y . Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol J Cell Physiol 1981 107: 283–293
Bannai S . Exchange of cystine and glutamate across plasma membrane of human fibroblasts J Biol Chem 1986 261: 2256–2263
Watanabe H, Bannai S . Induction of cystine transport activity in mouse peritoneal macrophages J Exp Med 1987 165: 628–640
Gmünder H, Eck H-P, Benninghoff B, Roth S, Dröge W . Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine Cell Immunol 1990 129: 32–46
Gout PW, Buckley AR, Simms CR, Bruchovsky, N . Novel lymphoma growth-inhibitory activity of the immunosuppressant, sulfasalazine. Proc 11th Int Congress Endocrinology, Sydney, Australia, October 29–November 2, 2000, p 313, No. P873 (Abstr.)
Kluin-Nelemans HC, Limpens J, Meerabux J, Beverstock GC, Jansen JH, de Jong D, Kluin PM . A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21) Leukemia 1991 5: 221–224
Krumenacker JS, Buckley DJ, Leff MA, McCormack JT, de Jong G, Gout PW, Reed JC, Miyashita T, Magnuson NS, Buckley AR . Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2 and bax expression Endocrine 1998 9: 163–170
Tomayko MM, Reynolds CP . Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother Pharmacol 1989 24: 148–154
Bannai S, Kasuga H . Anti-inflammatory drug inhibition of transport of cystine and glutamate in cultured human fibroblasts Biochem Pharmacol 1985 34: 1852–1854
Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J . Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays Can J Physiol Pharmacol 1997 75: 1088–1095
Ding XZ, Tong WG, Adrian TE . Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells Anticancer Res 2000 20: 2625–2631
Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C . Indomethacin serum concentrations in man Ann Rheum Dis 1976 35: 333–338
Kurowski M, Dunky A . Transsynovial kinetics of piroxicam in patients with rheumatoid arthritis Eur J Clin Pharmacol 1988 34: 401–406
Slattery JT, Levy G . Effect of ibuprofen on protein binding of warfarin in human serum J Pharm Sci 1977 66: 1060
Insel PA . Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout In: Hardman JG, Goodman Gilman A, Limbird LE (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th edn McGraw-Hill: New York 1996 pp 617–657
Ishii T, Bannai S, Sugita Y . Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine J Biol Chem 1981 256: 12387–12392
Kopp E, Ghosh S . Inhibition of NF-kappa B by sodium salicylate and aspirin Science 1994 265: 956–959
Wahl C, Liptay S, Adler G, Schmid RM . Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B J Clin Invest 1998 101: 1163–1174
Hoult JR . Pharmacological and biochemical actions of sulphasalazine Drugs 1986 32: (Suppl. 1) 18–26
Bach MK, Brashler JR, Johnson MA . Inhibition by sulfasalazine of LTC synthetase and of rat liver glutathione S-transferases Biochem Pharmacol 1985 34: 2695–2704
Guastavino E, Litwin NH, Heffes Nahmod L, Licastro R . Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment Acta Gastroenterol Latinoam 1988 18: 107–113
Rahav G, Zylber-Katz E, Rachmilewitz D, Levy M . Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases Isr J Med Sci 1990 26: 31–34
Almer S, Norlander B, Strom M, Osterwald H . Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission Scand J Gastroenterol 1991 26: 327–335
Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RGB, Rudman D . Plasma cysteine, cystine, and glutathione in cirrhosis Gastroenterology 1984 87: 770–776
Sato H, Tamba M, Ishii T, Bannai S . Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins J Biol Chem 1999 274: 11455–11458
Iwata S, Hori T, Sato N, Hirota K, Sasada T, Mitsui A, Hirakawa T, Yodoi J . Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion J Immunol 1997 158: 3108–3117
Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS . NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis Mol Cell Biol 1999 19: 5923–5929
Keating MJ, Holmes R, Lerner S, Ho DH . L-Asparaginase and PEG asparaginase – past, present and future Leuk Lymphoma 1993 10: 153–157
Uren JR, Lazarus H . L-Cyst(e)ine requirements of malignant cells and progress toward depletion therapy Cancer Treat Rep 1979 63: 1073–1079
Wada K, Kamisaki Y, Kitano M, Nakamoto K, Itoh T . Protective effect of cystathionine on acute gastric mucosal injury induced by ischemia-reperfusion in rats Eur J Pharmacol 1995 294: 377–382
Stabler SP, Lindenbaum J, Savage DG, Allen RH . Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency Blood 1993 81: 3404–3413
Kato S, Negishi K, Mawatari K, Kuo CH . A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion Neuroscience 1992 48: 903–914
Aoshiba K, Yasui S, Nishimura K, Nagai A . Thiol depletion induces apoptosis in cultured lung fibroblasts Am J Respir Cell Mol Biol 1999 21: 54–64
Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ . Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion J Neurosci 1998 18: 6241–6253
Acknowledgements
Dr CT Beer and Dr MC Robertson (BC Cancer Agency, Canada) are thanked for helpful discussions, and DJ Buckley (Cincinnati Medical Center, USA) for preparing the northern blots. Dr S Bannai (University of Tsukuba, Ibaraki, Japan) is thanked for providing the 4F2hc and xCT cDNA probes, and the Department of Advanced Therapeutics of the BC Cancer Agency for supplying DoHH2 cells. This study was supported by the BC Cancer Foundation, with core support from the BC Cancer Agency (PWG), and in part by NIH grant No. DK53452 and the Ohio Cancer Research Associates (ARB).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gout, P., Buckley, A., Simms, C. et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drug. Leukemia 15, 1633–1640 (2001). https://doi.org/10.1038/sj.leu.2402238
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402238
Keywords
This article is cited by
-
POLQ inhibition attenuates the stemness and ferroptosis resistance in gastric cancer cells via downregulation of dihydroorotate dehydrogenase
Cell Death & Disease (2024)
-
Ferroptosis: potential targets and emerging roles in pancreatic diseases
Archives of Toxicology (2024)
-
The emerging roles of MAPK-AMPK in ferroptosis regulatory network
Cell Communication and Signaling (2023)
-
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy
Experimental Hematology & Oncology (2023)
-
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Signal Transduction and Targeted Therapy (2023)